Professor Ioannis Kokkoris comments on the deal for Bloomberg.
Ioannis Kokkoris, Professor of Competition Law and Economics; Dean for International, Faculty of Humanities and Social Sciences at Queen Mary University of London, spoke to Bloomberg about the battle Illumina Inc. faces to save its $8 billion bid for cancer-test provider Grail from a European Union veto ahead of a Friday deadline to allay antitrust concerns. Professor Kokkoris said: “There seems to be just one way forward for this which would be a break-up” of the business,. I don’t think a long-term behavioral access remedy will do it here,” he said, referring to the type of proposal made to U.S. watchdogs.